BioSpace News Archive

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtual fireside chat at the BMO 2020 Growth and ESG Conference at 3:00 p.m. E.T. on Tuesday, December 8, 2020 .

Rocket Pharmaceuticals to Hold Webcast for Investors Highlighting Data Presented at the 62 nd American Society of Hematology Annual Meeting — Rocket Management to Discuss Data Updates from the Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I) and Pyruvate Kinase Deficiency (PKD) Programs —

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of data from a Phase 2 study evaluating umbralisib, the Company’s investigational once daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy, in Blood , the Journal of the American Society of Hematology. Michael S. Weiss, the Company’s Executive Chairman and Chi

Hua Gong, M.D., Ph.D. , appointed Chief Operating Officer and Head of Precision Medicine JC Xu, M.D., Ph.D., appointed Chief Scientific Officer Qinghai Zhao, Ph.D., appointed Chief Manufacturing Officer Company establishes presence in San Diego as a C enter of E xcellence for P recision M edicine

Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., today announced that it has filed its Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test with the U.S. Food and Drug Administration (FDA) for 510(k) premarket clearance

NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced positive findings from an independent evaluation of its UroShield® device on patients who have used the device for up to two years.

The global neonatal intensive care respiratory devices market is all set to gather handsome amount in the form of revenues during the forecast period of 2018 to 2026.

Dassault Systèmes joins a growing group of companies that are setting emissions reduction targets in line with what climate science says is necessary

Automated deep learning analysis of abdominal CT images produces a more precise measurement of body composition and predicts major cardiovascular events, such as heart attack and stroke, better than overall weight or body mass index, according to a study presented at the annual meeting of the Radiological Society of North America.

Led by Rock Springs Capital with participation by funds and accounts advised by T. Rowe Price Associates, Inc., Andreessen Horowitz, and other major investors